Clinical trial
An Open-Label Extension Study of EryDex in Patients With Ataxia Telangiectasia Following Participation in Study IEDAT-04-2022 (NEAT)
NCT06664853 is registered in ClinicalTrials.gov with Quince Therapeutics S.p.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Extension Study of EryDex in Patients With Ataxia Telangiectasia Following Participation in Study IEDAT-04-2022 (NEAT)
- Lead sponsor
- Quince Therapeutics S.p.A.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- December 11, 2024
- Completion date
- January 30, 2026
- Enrollment
- 101 (actual)
- Sites
- 21
Conditions
As the registry lists them; a condition with its own page is linked.